CAR T Cells and BIS Specifics - What's Going to Happen?

As CAR T cells have gotten approved, we've been able to do CAR T cells a little bit earlier. We're not doing it in patients who have like very bulky disease. And when we see that, we are seeing less in terms of toxicity. I do think the same thing is going to happen with vice-specifics as well. As of right now, who's getting by specifics? Patients who have absolutely no other option, who have very high disease burden. Those are the patients where you will end up seeing troubles with.